The cell-cycle effects of mTORC1 are not fully understood. We provide evidence that mTOR-raptor phosphorylates SGK1 to modulate p27 function. Cellular mTOR activation, by refeeding of amino acid-deprived cells or by TSC2 shRNA, activated SGK1 and p27 phosphorylation at T157, and both were inhibited by short-term rapamycin treatment and by SGK1 shRNA. mTOR overexpression activated both Akt and SGK1, causing TGF-b resistance through impaired nuclear import and cytoplasmic accumulation of p27. Rapamycin or raptor shRNA impaired mTOR-driven p70 and SGK1 activation, but not that of Akt, and decreased cytoplasmic p27. mTOR/raptor/SGK1 complexes were detected in cells. mTOR phosphorylated SGK1, but not SGK1-S422A, in vitro. SGK1 phosphorylated p27 in vitro. These data implicate SGK1 as an mTORC1 (mTOR-raptor) substrate. mTOR may promote G1 progression in part through SGK1 activation and deregulate the cell cycle in cancers through both Akt-and SGK-mediated p27 T157 phosphorylation and cytoplasmic p27 mislocalization.
INTRODUCTION
Cell-cycle progression is governed by cyclin-dependent kinases (Cdks) that are activated by cyclin binding and inhibited by two families of Cdk inhibitors (Sherr and Roberts, 1999) . p27, a member of the kinase inhibitor protein (KIP) family, was discovered in cells arrested by transforming growth factor-b (TGF-b), by contact inhibition, and by lovastatin (Sherr and Roberts, 1999) . p27 acts in G0 and early G1 to inhibit E-type cyclin-Cdk2 complexes. p27 also facilitates the assembly and activation of cyclin D-Cdks in early G1 phase (Chu et al., 2008) .
Cell-cycle deregulation is a hallmark of cancer. Loss of the Cdk inhibitory function of p27 confers an advantage during cancer progression and occurs through at least two mechanisms: increased p27 proteolysis and cytoplasmic mislocalization away from nuclear targets. p27 turnover can be increased in cancers through activation of receptor tyrosine kinases (Chu et al., 2008) , activation of Abl and Src (Chu et al., 2007; Grimmler et al., 2007) , overexpression of the ubiquitin ligase component SKP2 (Chu et al., 2008) , and by changes in Cks1 and increased cyclin E Strohmaier et al., 2001 ), all of which promote the phosphorylation of p27 on threonine 187 (T187) required for ubiquitin-dependent p27 degradation (Carrano et al., 1999; Vlach et al., 1997; Sheaff et al., 1997) . Recent data also implicate miRNA in reduced p27 protein in cancers (le Sage et al., 2007) .
Akt acts downstream of PI3K to phosphorylate p27 at T157 and T198, leading to impaired nuclear p27 import, p27 accumulation in the cytoplasm, and loss of cyclin E-Cdk2 inhibition (Viglietto et al., 2002; Shin et al., 2002; Liang et al., 2002; Motti et al., 2004) . Since PI3K activates multiple effectors, we investigated if other PI3K-dependent kinases may regulate p27 localization.
The mammalian target of rapamycin (mTOR) is a central regulator of cell growth that is activated by receptor tyrosine kinasemediated PI3K activation. mTOR exists in two distinct multiprotein complexes. The mTORC1 complex includes mTOR, raptor, and mLST8 Hara et al., 2002; Loewith et al., 2002) and regulates protein synthesis through phosphorylation of p70 S6K and 4EBP1 (Burnett et al., 1998; Brown et al., 1995) .
mTORC2, comprising mTOR, rictor, and mLST8, phosphorylates Akt on S473 (Sarbassov et al., 2005; Hresko and Mueckler, 2005) . mTOR also regulates the cell cycle. mTORC1 inhibition by rapamycin arrests the cell cycle (Nourse et al., 1994) , and lowdose rapamycin restores G1 arrest by TGF-b in resistant cells (Law et al., 2002) . Activation of mTOR through genetic loss of its upstream inhibitor, TSC2, has been shown to mislocalize p27 to the cytoplasm and reduce p27-cyclin E-Cdk2 complexes (Soucek et al., 1998) , but mechanisms linking mTOR and p27 cytoplasmic localization have not been fully elucidated.
The serum-and glucocorticoid-inducible kinase (SGK), another downstream effector of PI3K, is phosphorylated and activated by PDK1 (Biondi et al., 2001; . SGK belongs to the AGC family, which includes PKA, Akt/PKB, PKC, PKG, p90 RSK , and p70 S6K (Peterson and Schreiber, 1999) . SGK1 is 54% homologous to Akt/PKB (hereafter referred to as Akt) within its catalytic domain (Webster et al., 1993) and has a consensus motif (KKRNRRLSVA) similar to that of Akt (RXRXXS/T) . Both Akt and SGK can cooperate to phosphorylate substrates including GSK3-b, B-Raf, and FKHRL1 Cross et al., 1995; Sakoda et al., 2003; Zhang et al., 2001; Brunet et al., 1999 Brunet et al., , 2001 , suggesting that SGK may, like Akt, regulate cell-cycle progression. SGK translocates from the cytoplasm to the nucleus following serum stimulation Maiyar et al., 2003) . These observations raise the possibility that SGK might act in concert with Akt to phosphorylate p27 (Viglietto et al., 2002; Shin et al., 2002; Liang et al., 2002; Motti et al., 2004) .
Here we provide evidence that SGK1 is an mTOR-raptor substrate and that SGK1 in turn phosphorylates p27. Knockdown of SGK1 impaired p27 phosphorylation at T157 following activation of cellular mTORC1 by refeeding of amino acid starved-cells. mTOR-dependent activation of both Akt and SGK1 may contribute to p27 dysfunction in cancers.
RESULTS
mTOR Overexpression Causes TGF-b Resistance and Cytoplasmic p27 Mislocalization mTOR transfected clones of the melanoma line, WM35, showed increased total and phosphorylated mTOR, activation of p70 S6K , and unchanged total p70 S6K (representative clones, Figure 1A ). While parental WM35 and empty vector control clone WM35-PC1 were arrested by TGF-b, mTOR overexpression impaired G1 arrest by TGF-b (representative data, Figure 1B ).
Since p27 is required for G1 arrest by TGF-b (Donovan et al., 2002) , p27 regulation was assayed in the mTOR clones. While p27 is largely nuclear in WM35 and WM35-PC1, p27 localized to both nucleus and cytoplasm in mTOR clones (Figure 2A ). This appears not to be p70 S6K dependent since overexpression of constitutively activated p70 S6K did not mislocalize p27 to the cytoplasm ( Figure 2B ). Phosphorylation of p27 at threonine 157 (T157) impairs nuclear p27 import. Since both T157 and threonine 198 (T198) lie within putative AGC kinase motifs (Liang et al., 2002; Fujita et al., 2002) , effects of these sites on p27 mislocalization by mTOR were assayed. Transfected YFPp27 accumulated in the cytoplasm in mTOR clones but was nuclear in WM35 and WM35-PC1 ( Figure 2C ; N:C quantitation in Table S1 available online) . Phosphomimetic mutants, YFPp27T157D and YFPp27T198D, were predominantly cytoplasmic in WM35 and WM35-PC1. YFPp27T157A, YFPp27T198A, and YFPp27T175AT198A localized to nuclei in all cell types ( Figure 2D ). Thus, in mTOR overexpressing cells, T157 and T198 phosphorylation mediate cytoplasmic accumulation of p27.
mTOR Delays Nuclear Import of p27 His tagged p27 (his-p27) was incubated with cytosolic extract from either WM35-PC1 or WM35-M15 and then assayed in vitro for import into isolated WM35-PC1 nuclei. Pretreatment of his-p27 with mTOR cell lysate delayed nuclear import of p27 compared to pretreatment with WM35-PC1 lysate (Figure 2E) . In negative control reactions, wheat germ agglutinin (WGA) or the absence of GTP abolished active nuclear p27 import.
SGK1 Activation by mTOR Is Rapamycin Sensitive
Akt activates mTOR by phosphorylating and inactivating the mTOR inhibitor, TSC2 (Krymskaya, 2003) . Moreover, mTOR/rictor also activates Akt (Sarbassov et al., 2005) . mTOR-overexpressing clones showed activation of both Akt and the related AGC kinase, SGK1, compared to WM35-PC1 ( Figure 3A ). While 10 nM rapamycin rapidly (within 15 min) inhibited SGK1 phosphorylation at S422 and at T256 and reduced p70pT389 and T157-phosphorylated p27 (p27pT157), pAkt was not affected by short duration rapamycin in WM35-PC1 ( Figure 3B ). Rapamycin (10 nM) had little effect on either SGK1 or AKT activation in mTOR-overexpressing clones, but at higher doses, rapamycin rapidly inhibited SGK1 and p70, but not Akt ( Figure 3B ).
Cellular mTOR-Driven p27T157 Phosphorylation Is Reduced by SGK1 shRNA We then tested conditions that activate endogenous cellular mTORC1 for effects on SGK1 and p27 phosphorylation. Stimulation of serum and estrogen starved MCF-7 cells (E2À) with insulin and estradiol (Ins + E2) increased phosphorylation of p70, SGK1, and p27 within 30 min, and this was blocked by brief pretreatment with rapamycin ( Figure 3C ). Readdition of amino acids (+aa) to starved cells (Àaa) rapidly increased p70pT389, SGK1pS422, and SGK1pT256 and p27pT157 and this was impaired by 15-60 min pretreatment with rapamycin in WM35-PC1 ( Figure 3D ). shRNA to SGK1 also impaired the rapid phosphorylation of p27 at T157 following refeeding of amino acid starved cells. Addition of rapamycin to SGK1 shRNA-transfected cells fully prevented T157 phosphorylation of p27 after aa refeeding ( Figure 3E ). mTOR Phosphorylates SGK1 Cellular mTOR immunoprecipitates from WM35 phosphorylated recombinant SGK1 in a time-and mTOR concentration-dependent manner ( Figure 4A ). Addition of rapamycin 15 min prior to mTOR precipitation abolished mTOR-mediated SGK1 phosphorylation in vitro. mTOR-bound raptor and PRAS40 were lost with brief rapamycin treatment while mTOR bound rictor and Sin1 were unchanged ( Figure 4B ). Similarly, mTOR was rapidly lost from raptor but not rictor immunoprecipitates following 15-60 min rapamycin ( Figure S1 ). The increased mTOR expression in WM35-M15 was reflected in its greater activity toward SGK1 compared to that in WM35 ( Figure 4C ). SGK1 phosphorylation at T256 and at S422 is required for full kinase activation (Tessier and Woodgett, 2006) . Mutation converting S422 to aspartic acid causes constitutive SGK1 activa- tion (Park et al., 1999) . SGK1 is phosphorylated by PDK1 at T256 , but the S422 kinase has not been previously described. Wildtype and mutant SGK1 variants (S422A and T256A) were used as substrates in mTOR in vitro kinase assays. mTOR phosphorylated SGK1-T256A to the same extent as SGK1-WT, but mTOR activity toward SGK1-S422A was markedly attenuated ( Figure 4D ).
To test if SGK1 phosphorylation at S422 affects that of T256 in cells, wildtype or mutant flag-tagged SGK1 were transiently expressed in WM35. T256 phosphorylation was attenuated in SGK1-S422A compared to SGK1-WT, while loss of the T256 phosphorylation site did not affect S422 phosphorylation ( Figure 5A ). This and the observation that rapamycin not only abolished cellular SGK1 phosphorylation at S422, but also attenuated SGK1pT256 ( Figures 3B, 3C , and 3D), indicate that S422 phosphorylation may promote that of T256.
Detection of mTOR-Raptor-SGK1 Complexes
The rapid loss of SGK1 phosphorylation with rapamycin implicates mTORC1 (mTOR-raptor) in SGK1 phosphorylation. Flag-SGK1 precipitates from cells transfected with WT or mutant SGK1 (S422A, T256A) contained mTOR, raptor, and the mTORC1 component PRAS40, but not rictor or the mTORC2 component Sin1. Cellular mTOR precipitates also contained SGK1 ( Figure 5B) .
A minimal consensus binding motif (FDXEL) on mTORC1 substrates p70 and 4EBP1 mediates their interaction with raptor (Nojima et al., 2003) . While SGK1 bears a putative raptor-binding consensus motif (F 385 DPEF), mutation of this site did not impair binding of SGK1-F385A to mTOR-raptor in WM35 ( Figure 5B ) nor Molecular Cell mTOR-Raptor Activates SGK1 to Phosphorylate p27 did it affect GST-SGK1-F385A binding to cellular mTOR and raptor in GST pulldowns in vitro. Rictor did not bind SGK1 in vitro ( Figure 5C ). SGK1-S422A and SGK1-T256A also bound mTOR and raptor but not rictor in GST pull downs ( Figure 5C ). Thus, SGK:mTORC1 interaction does not appear to require prior SGK1 phosphorylation, and is not altered by mutation converting F385DPEF to ADPEF.
SGK1 Phosphorylates p27
In Vitro and Constitutive SGK1 Increases p27pT157, Localizes p27 to Cytoplasm and Impairs TGF-b Arrest SGK1 phosphorylates p27 in vitro. His-p27 phosphorylation by recombinant SGK1 ( Figure 6A ) was diminished significantly when p27T157A and p27T198A were used as substrates ( Figure 6B ). Consistent with data in Figure 3 in which cellular mTORC1-dependent SGK1 activation increased p27pT157, WM35 lines stably expressing constitutive SGK1-S422D also showed increased p27pT157, while kinase-dead SGK1-K127M lines did not ( Figure 6C ). Reactivity with antibody raised against p27pT198 was too weak to adequately assess this site in these cells.
Constitutively active SGK1-expressing clones showed increased cytoplasmic p27 compared to WM35-PC1, while cellular p27 was predominantly nuclear in kinase-dead SGK1-K127M lines ( Figure 6D ). Moreover, transfected YFPp27 mislocalized to cytoplasm in activated SGK lines but was nuclear in kinasedead SGK1 and WM35-PC1 cells ( Figure 6E and Table S2 ). While TGF-b cause G1 arrest in WM35-PC1 and in cells overexpressing kinase dead SGK1 (WM35-K1), constitutively active (B) WM35-PC1 and WM35-M15 were treated with indicated rapamycin concentrations for 0 to 60 min, and phosphorylated and total SGK1, p70, Akt, and p27 were detected by blotting. (C) Serum starved MCF-7 cells were pretreated with 10 nM rapamycin for 0-60 min before stimulation with Insulin plus estradiol (Ins + E2) for 30 min. (D) Serum and aa starved WM35-PC1 were pretreated with 10 nM rapamycin for 0 to 60 min before readdition of aa for 30 min. (E) WM35-PC1 cells were infected with SGK1shRNA or not, and then aa starved and pretreated with or without 10 nM rapamycin for 30 min before refeeding aa for 30 min (C, D, and E) Phospho-and total levels of SGK1, p70, and p27 at 30 min after mitogens are shown.
SGK1 conferred partial resistance to TGF-b in WM35-S2 ( Figure 6F ).
mTOR-Driven p27 Phosphorylation and Mislocalization Is both Rictor and Raptor Mediated
Since mTOR activates both Akt and SGK1, the cytoplasmic mislocalization of p27 in mTOR-overexpressing cells could theoretically result from action of both kinases. Akt activation by mTOR is resistant to short-term rapamycin and mediated by mTOR complex 2. To further establish that mTORC1 drives SGK1 activation and to test effects of mTORC1 and mTORC2 inhibition on p27 phosphorylation and localization, WM35-M15 was infected with lentiviral shRNA to either raptor or rictor. Raptor shRNA reduced raptor expression, decreased SGK1pS422, SGK1pT256, and p70pT389, but did not affect total SGK1, total Akt, or S473-and T308-phosphorylated Akt ( Figure 7A ). Conversely, rictor shRNA decreased AktpS473 but did not change total Akt nor affect p70 or SGK1 levels or phosphorylation ( Figure 7A ). p27pT157 was attenuated by knockdown of either raptor or rictor ( Figure 7A ).
The cytoplasmic mislocalization of YFPp27 in WM35-M15 appears to be both raptor-and rictor-dependent, since nuclear p27 localization was partially restored by knocking down either raptor or rictor. Infection of both lentiviruses together further increased nuclear p27 localization ( Figure 7B and Table S3 ).
Knockdown of SGK1 attenuated p27 phosphorylation at T157 in proliferating WM35-M15 while control shRNA did not ( Figure 7C ). While shRNA to both raptor and rictor maximized the nuclear localization of p27, short-term rapamycin treatment of this same line at a dose that inhibits SGK1, but not Akt (Figure 3B) , was sufficient to restore nuclear p27 localization, further supporting a role for mTORC1-driven SGK1 activation in the cytoplasmic mislocalization of p27 ( Figure 7D and Table S4 ). Rapamycin ( Figure 7D ) may have more completely inhibited SGK1 activity than did incomplete raptor knockdown by shRNA ( Figure 7B ).
TSC2 Loss Drives mTORC1-Dependent SGK1 Activation and p27 Phosphorylation Loss or inactivation of TSC2 activates cellular mTOR. TSC2 knockdown in WM35 increased mTOR phosphorylation, AktpS473, SGK1pS422, and p27pT157 ( Figure 7E ). Concurrent knockdown of both TSC2 and SGK1 attenuated p27 phosphorylation at T157, supporting a role for SGK1 in p27 phosphorylation following activation of cellular mTOR ( Figure 7E ). mTOR is also activated in the TRI102 human renal angiomyolipoma cell line with a hemizygous inactivating mutation of TSC2 derived from a TSC syndrome patient. Wild-type TSC2 was stably reintroduced to generate the TRI103 cell line. SGK1pS422 was increased in TRI102 compared to TRI103, in both serum-starved cells and 30 min following serum addition. Brief rapamycin pretreatment abolished serum-stimulated SGK1 phosphorylation at S422 while loss of SGK1pT256 and p27pT157 followed that of SGK1pS422 ( Figure 7F ). Tsc2 À/À MEFS (Zhang et al., 2003) also showed increased SGK1pS422, p70pT389, and pAkt both before and after serum stimulation compared to TSC2 +/+ MEFS. Rapamycin rapidly inhibited phosphorylation of both SGK and p70, while pAkt was unchanged ( Figure 7G ).
DISCUSSION
mTOR promotes cell proliferation, and mTORC1 activates S6K and eIF4E (Abraham and Wiederrecht, 1996; Burnett et al., 1998) to increase translation of positive cell-cycle regulators, such as cyclin D1 and c-Myc (Gera et al., 2004) . Genetic loss of the mTOR inhibitor, TSC2, reduces p27-cyclin E-Cdk2 complexes and causes p27 mislocalization to the cytoplasm (Soucek et al., 1998) , but the mechanism underlying this was not known.
The present work provides evidence that SGK1 is an mTORC1 substrate and links mTORC1 and cell-cycle regulation by demonstrating that cellular mTORC1 drives SGK1-dependent T157 phosphorylation of p27. mTORC1 activation by refeeding starved cells with amino acids or estrogen and insulin increased both SGK1pS422 and p27pT157. TSC2-deficient human angiomyolipoma cells and Tsc2 À/À MEFs both showed greater pSGK1 after serum starvation refeeding compared to TSC2-expressing counterparts. Tsc2 À/À MEFs had activated SGK1, p70, and Akt, but only SGK1 and p70 were rapamycin sensitive. Similarly, mTOR activation by TSC2 knockdown in WM35 activated both Akt and SGK1, but only the latter was inhibited by rapamycin. These data and the rapid inhibition of SGK1 by raptor shRNA are consistent with a role for mTORC1 in SGK1 activation. In all cases where mTORC1 activated human SGK1, p27pT157 was increased and this was dramatically reduced by knockdown of SGK1, supporting a role for SGK1 in p27 phosphorylation in vivo. The incomplete loss of p27pT157 following SGK1 shRNA may reflect incomplete knockdown of SGK1 or the presence of other mTORC1 driven kinases that act on p27. SGK1 may act in early G1 to phosphorylate p27 at T157 and promote assembly of D-type cyclin-Cdks (M.D.L., J. Liang, and J.M.S., unpublished data). Signaling pathways that activate mTOR are altered in many human cancers. Mutational Ras and Akt activation, amplification of PI3K, and mutation or loss of PTEN occur in a majority of human cancers (Vivanco and Sawyers, 2002) . While PI3K activates many effectors in addition to mTOR, hamartoma development in Tuberous Sclerosis Syndrome patients who inherit TSC1 or TSC2 mutations (Jones et al., 1999) and elevated Rheb activity in cancer lines indicate an oncogenic role for mTOR activation. mTORC1 inhibitors have shown promise as antineoplastic agents. The rapamycin derivative, CCI-779, inhibits PTEN-deficient cell proliferation ) and tumor development (Podsypanina et al., 2001) , and the mTORC1 inhibitor, RAD001, reverses Akt-dependent prostate intraepithelial neoplasia (Majumder et al., 2004) . While mTORC1 inhibitors have shown initial efficacy in clinical trials in human cancers (Chan et al., 2005; Cho et al., 2007) , the mechanisms whereby mTOR contributes to tumorigenesis are not fully understood. p27 phosphorylation at T157 impairs its nuclear import (Liang et al., 2002) . Oncogenic mTOR may constitutively activate both Akt and SGK1, leading to accumulation of cytoplasmic p27. shRNA to raptor and shRNA to rictor each partly restored nuclear localization of YFP-p27, while both together effectively redistributed p27 to the nucleus in mTOR overexpressing cells. mTORdriven mislocalization of p27 was abolished by mutations converting p27T157 and T198 to alanine, and these mutations also reduced p27 phosphorylation by SGK1 in vitro. While Akt activation alone would be sufficient for the p27 mislocalization and TGF-b resistant phenotypes observed with mTOR overexpression, the downregulation of p27pT157 following SGK1 shRNA in WM35-M15 and relocalization of p27 to the nucleus by raptor shRNA or rapamycin indicate that cellular SGK1 contributes to effects of constitutive mTOR action on p27. Cytoplasmic p27 may be pro-oncogenic by contributing to increased cell motility (Besson et al., 2004) . SGK1 belongs to the AGC kinase family. AGC kinases, including PKA (Cheng et al., 1998) , PKB (Stokoe et al., 1997) , PKC (Le Good et al., 1998), p70 S6K , and SGK (Park et al., 1999; , all contain a conserved A loop targeted for activating phosphorylation by PDK1. SGK1 activation requires phosphorylation of at least two sites. PDK1 binds phospho-S422 in the hydrophobic motif (H-motif) of SGK1 to phosphorylate T256 Biondi et al., 2001) . The H-motif kinase that phosphorylates SGK1 at S422 to prime it for phosphorylation by PDK1 had not been identified. mTOR is a good SGK1 H-motif kinase candidate, since it phosphorylates the H-motifs of Akt at S473 (Sarbassov et al., 2005) and p70 S6K at T389 (Burnett et al., 1998) . In vitro phosphorylation by mTOR was markedly reduced in SGK1-S422A compared to SGK1-WT, but unchanged in SGK1-T256A. mTOR activation increased cellular SGK1pS422 and SGK1pT256. Although both were reduced by rapamycin and by raptor shRNA, the decline in SGK1pT256 always followed that of SGK1pS422. Moreover, SGK1-S422A showed reduced reactivity with (B) Anti-Flag SGK1 precipitates were resolved by SDSPAGE and mTOR, raptor, PRAS40, rictor, sin1 and Flag-SGK1 immunoblotted. Cellular mTOR precipitates (IP mTOR) were resolved and associated proteins detected. (C) SGK1 binds mTOR in vitro. Cell lysates were incubated with GST or GST-SGK1 (WT, S422A, T256A, and F385A), recovered on glutathionesepharose 4B and were resolved by SDSPAGE and associated mTOR, raptor, rictor, and SGK1 detected by blotting.
SGK1pT256 antibody in WM35 cells, suggesting that phosphorylation of S422 may prime that of T256. mTOR may also phosphorylate SGK1 on other sites, since SGK1-S422A retained minimal phosphorylation by mTOR in vitro. Alternatively, this may reflect comigration of cellular SGK1 from the mTOR kinase precipitates with SGK1-S422A.
While raptor-mTOR-SGK1 complexes coprecipitate, complex formation does not require prior SGK1 phosphorylation since both SGK1-S422A and SGK1-T256A bound mTOR-raptor. SGK1 has a FDPEF motif similar to the FDXEL motifs of p70 S6K and 4EBP1 implicated in raptor binding (Nojima et al., 2003) . SGK1-F 385 DPEF did not abrogate binding to mTOR and raptor; thus, SGK1 may bind raptor through additional sites or through an adaptor protein and/or bind directly to mTOR. Phosphorylation of SGK1 by mTOR may be cell-type dependent. Hyperphosphorylation of SGK1 by PDK1 was not inhibited by rapamycin in H293 cells (Park et al., 1999) . We found rapamycin inhibited SGK1 in WM35, MCF7, MDA-MB-231, HeLa, and EMT6 cells, but not in MDA-MB-361 cells (data not shown). PI3K and mTOR-raptor-independent pathways may also activate SGK1.
SGK1 overexpression is observed in cancers (Chung et al., 2002; Adeyinka et al., 2002) and may promote cancer cell proliferation through multiple pathways, including effects on FOXO3a, c-fms, and NF-kB (Wu et al., 2006; Tangir et al., 2004; Zhang et al., 2005) and inhibition of MEKK3 (Chun et al., 2003) . As for Akt, SGK phosphorylates bRaf, GSK3-b, and FKHRL1 (Kobayashi et al., 1999; Cross et al., 1995; Sakoda et al., 2003; Zhang et al., 2001; Brunet et al., 1999 Brunet et al., , 2001 . SGK1 actively shuttles between cytoplasm in G1 and nucleus in S and G2/M Maiyar et al., 2003) . Phosphorylation of p27 by SGK1 in early G1 may delay nuclear import of newly synthesized p27 to facilitate D type cyclin-Cdk assembly. In cancer cells, oncogenic activation of PI3K and mTOR pathways may recruit SGK1 and other AGC kinases to drive cytoplasmic mislocalization of p27, thereby impairing its inhibition of cyclin-Cdk2. SGK1 is overexpressed in up to 48% (Sahoo et al., 2005) , and Akt is overexpressed in 40%-60% of primary human breast cancers (Viglietto et al., 2002; Shin et al., 2002; Liang et al., 2002; Motti et al., 2004) . Both may have complementary cell-cycle promoting effects in these cancers through deregulation of p27. mTOR inhibitors and strategies that target both Akt and SGK1 may more effectively impair cancer growth than inhibition of either kinase alone.
EXPERIMENTAL PROCEDURES
Antibodies and Western Blotting Western blotting was as described (Sandhu et al., 1997) . Antibodies to mTOR, phospho-mTOR, raptor, rictor, Akt, and phospho-Akt (S473, T308) were from Cell Signaling; antibodies to SGK1 and phospho-SGK1 (T256 and S422) were from Upstate Biotechnology; antibodies to p70, phosphor-p70 (T389), PRAS40, and b-tubulin were from Santa Cruz Biotechnology; antibodies to sin1 were from Bethyl; antibodies to p27 were from Transduction Labs; and antibodies to b-actin were from Sigma. Anti-p27pT157 and -p27pT198 antibodies were from R&D.
Cell Culture WM35 was grown in RPMI 1640 with 5% FBS as in Liang et al. (2002) . For aa deprivation, WM35 was grown without serum overnight in an aa-free medium. Amino acid cocktail was then added with or without prior rapamycin (10 nM), and cells were recovered 30 min later. MCF-7 cells were grown in DMEM with 10% FBS. For starvation refeeding, MCF-7 cells were grown without serum Figure 6 . SGK1 Phosphorylates p27 In Vitro and In Vivo (A) Recombinant SGK1 (0, 50, or 100 ng) was incubated with His-p27 using kinase assay conditions. Products were resolved, and radioactivity in p27 was quantitated by phosphorimager. (B) p27T157A and p27T198A phosphorylation by SGK1 is less than p27WT (graphed with ± SEM). (C) SGK1 overexpression increases p27pT157 in vivo. Total p27 and p27pT157 were detected in WM35-PC1 (PC1) and in WM35 clones stably overexpressing constitutively activated SGK1-S422D (S2, S3, and S4) or kinase-dead SGK1 (KD1, KD2, and KD3). Table S2 ). (F) SGK1 overexpression impairs G1 arrest by TGF-b. Cells were treated with (gray bars) or without (black bars) 10 ng/ml of TGF-b for 48 hr, and then cell-cycle distribution was assayed by flow cytometry. %S ± SEM is graphed. overnight, and then Insulin 10 nM and estradiol 10 À8 M were added for 30 min with or without prior rapamycin 10 nM. The TRI102 cell line was generated by introduction of E6/E7 (pLXSN 16E6E7-neo) (Furukawa et al., 1996) and human telomerase (pLXSN hTERT-hyg) into a primary culture of TSC2 null human angiomyolipoma cells as described in Yu et al. (2004) . TRI103 was generated by stable transfection of TRI102 with wild-type TSC2 (pcDNA3.1 TSC2-zeo). TRI102 and TRI103 were maintained in DMEM + 10% FBS. The Tsc2 À/À and Tsc2 +/+ MEFS were cultured as described (Zhang et al., 2003) .
Plasmid Site-Directed Mutagenesis and Transfection
Derivation of human YFPp27WT, YFPp27T157A, and YFPp27T157D was previously described (Liang et al., 2002) . T198 of p27 was replaced with alanine (p27T198A) or aspartic acid (p27T198D) using QuickChange site-directed mutagenesis (Strategene). Full-length mTOR cDNA was ligated into pcDNA3.1. Constitutively activated p70 S6K1 plasmid was provided by M. Oft. c-myctagged and Flag-tagged wild-type, constitutive active (S422D), and kinasedead (K127M) SGK1 plasmids were provided by D. Pearce (Bhalla et al., 2005) . S422A, T256A, and F385A SGK1 were generated using QuickChange Site-Direct-mutagenesis (Stratagene). Transfection used LipofectAMINE/ PLUS (Invitrogen). Stable cell lines were selected in G418 (200 mg/ml).
Flow Cytometry
Cells were pulse-labeled with 10 mM bromodeoxyuridine (BrdU) and stained with anti-BrdU-conjugated FITC (Becton Dickinson), and propidium iodide and cell-cycle distribution was assayed by flow cytometry as described (Sandhu et al., 1997) .
Intracellular Localization of p27
Nuclear cytoplasmic fractionation was carried out as described (Liang et al., 2002) . Equal cell volumes of nuclear and cytoplasmic lysates were assayed for cellular p27 by immunoblotting. Nuclear RCC1 and cytoplasmic b-tubulin were blotted as fractionation controls. For fluorescence localization, cells were transfected with YFPp27 and p27 detected by fluorescence microscopy at 24 hr. Nuclear/cytoplasmic YFPp27 distribution was quantitated by counting 100 cells in three different low power (103) fields. Photographs were taken at 4003 magnification using an Empix digital camera and ''CoolSnap'' software (Photomajics).
Nuclear Import Assay Cells were digitonin permeabilized, and nuclei were incubated with cytosol, an ATP-regenerating system, and his-p27 for 60 min at 21 C. Nuclear and supernatant fractions were immunoblotted for His-p27. Where indicated, His-p27 was preincubated with cytosolic protein from WM35-PC1 or WM35-mTOR Figure 7 . Evidence for mTOR-Raptor Effects on SGK-Phosphorylation and p27 Localization (A and B) WM35-M15 was infected with lentiviral shRNA to silence raptor or rictor (A). Raptor, rictor, and phospho-and total SGK1, p70, Akt, and p27 levels are shown. (B) YFP-p27 localization in WM35-M15 after silencing raptor, rictor, or both.
(C) WM35-M15 was infected with SGK1shRNA, and phospho-and total SGK1, p70, Akt, and p27 were detected by blotting. (D) YFPp27 localization 24 hr posttransfection into WM35-PC1 and WM35-M15 and rapamycin treatment for 0 to 60 min. (E) WM35 cells were infected with TSC2shRNA alone or together with SGK1shRNA. TSC2 and total and phosphorylated mTOR, SGK1, Akt, and p27 are shown. (F) Human angiomyolipoma (TRI102) and TSC2-transfected TRI103 cells were serum starved for 18 hr (ÀFBS), and then 10 nM rapamycin was added 15-60 min prior to serum stimulation for 30 min (+FBS). Indicated proteins are immunoblotted.
(G) Tsc2 À/À and Tsc2 +/+ MEFs were serum starved for 18 hr (ÀFBS), then 10 nM rapamycin (Rapa) was added for 60 min prior to serum readdition (+FBS), and cells were lysed for immunoblotting.
prior to import assays. Preincubation with wheat germ agglutinin (200 mg/ml) and reactions carried out without GTP abolished active p27 import and served as negative controls.
Recombinant Protein, Affinity Purification, and Kinase Assays p27WT, p27T157A, p27T157D, p27T198A, and p27T198D cDNAs were subcloned into pET28a as described (Liang et al., 2002) . His-p27 was purified on nickel-agarose beads. For mTOR kinase assays, mTOR was precipitated from 200-1000 mg cellular lysate and 400 ng recombinant SGK1 used as substrate (Upstate Biotechnology) as described (Drenan et al., 2004) in 30 ml reaction buffer (10 mM HEPES [pH 7.5], 50 mM NaCl, 50 mM b-glycerophosphate, 1 mM DTT, 10 mM MgCl2, 4 mM MnCl2, 300 mM ATP, and 6 mCi/tube g 32 P-ATP). Products were resolved, gels were dried, and radioactivity was quantitated by phosphoimager. SGK1 activity against his-p27 substrate was assayed and quantified as in Yang et al. (2006) .
GST Pull-Down Assay
Full-length murine WT and mutant SGK1 (S422A, T256A, and F385A) cDNAs were subcloned into pGEX-3X vector. GST fusion proteins were isolated on glutathione-Sepharose 4B beads (Amersham Biosciences). Cell lysates were incubated with GST alone or GST-SGK1 (WT or mutants) and glutathione-Sepharose 4B beads at 4 C for 3 hr, washed thrice, boiled in Laemmli buffer, and resolved by SDS-PAGE.
Lentiviral shRNA Production and Infection
Lentivirus vectors encoding raptor, rictor, TSC2, or SGK1 shRNA were cotransfected together with the Delta VPR and CMV VSVG plasmids (Addgene) into actively growing HEK293T using FuGENE (Roche) as described (Sarbassov et al., 2005) . Viral supernatants were collected 36 and 72 hr later, concentrated by ultracentrifugation for 2 hr at 4 C, and resuspended overnight at 4 C in 1/600th of the original volume. Cells were infected twice in the presence of 6 mg/ml protamine sulfate, selected for puromycin resistance, and analyzed 3-7 days postinfection.
SUPPLEMENTAL DATA
The Supplemental Data include one figure and four tables and can be found with this article online at http://www.molecule.org/cgi/content/full/30/6/701/ DC1/.
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